
Vyome Holdings, Inc
67
Recent developments highlight the merger recommendation, patent grants, regulatory certifications, and strategic distribution agreements.
- ReShape Lifesciences Board unanimously recommended a merger with Vyome Therapeutics and sale of assets to Biorad Medisys in July 2025 [N1].
- ReShape Lifesciences secured a U.S. patent for an innovative intragastric device aimed at enhancing weight loss solutions [N2].
- ReShape Lifesciences regained Nasdaq compliance with stockholders equity requirements as of June 2025 [N3].
- ReShape Lifesciences secured a key Australian patent for diabetes neuromodulation technology in June 2025 [N4].
- ReShape signed exclusive deals with Recon Supply to distribute devices across VA and DoD systems, targeting veteran and military healthcare solutions [N5][N6].
- ReShape Lifesciences achieved EU MDR and UKCA certification for medical devices, enhancing patient safety and market access in Europe [N7].
- ReShape Lifesciences reported first quarter 2025 financial results and strategic updates in May 2025 [N8].
Vyome Holdings, Inc is involved in the healthcare sector through its association with Vyome Therapeutics and a merger with ReShape Lifesciences. The combined entity focuses on innovative medical devices, including intragastric devices for weight loss and neuromodulation technologies for diabetes management. The company has secured patents in the US and Australia and achieved regulatory certifications in Europe, supporting its product development and market access. Distribution agreements target veteran and military healthcare systems in the US. Financially, the company reported modest revenue and a net loss in Q3 2026 but maintains strong liquidity ratios.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Vyome Holdings, Inc is engaged in a merger with ReShape Lifesciences, which has secured multiple patents and regulatory certifications for medical devices targeting weight loss and diabetes treatment. The company maintains strong liquidity as of Q3 2026 with a current ratio of 3.68 and cash ratio of 3.37, despite reporting a net loss for the quarter ending September 30, 2026 [S2].
The company benefits from a growing portfolio of patented medical technologies addressing weight loss and diabetes, supported by regulatory approvals and certifications that facilitate market access in Europe. Exclusive distribution agreements with Recon Supply enhance reach into veteran and military healthcare systems. The merger with ReShape Lifesciences consolidates complementary assets and expertise, potentially enabling operational synergies and expanded product offerings.
The company reported a net loss in the latest quarter and relatively low revenue, indicating ongoing challenges in achieving profitability. The medical device sector is competitive and subject to regulatory risks, and the success of the merger with ReShape Lifesciences depends on effective integration. Market adoption of new medical technologies can be uncertain, and reliance on exclusive distribution agreements may limit broader market penetration.
Vyome Holdings, Inc's moat is supported by its portfolio of patents covering innovative medical devices and neuromodulation technologies, regulatory certifications in key markets such as the EU and UK, and exclusive distribution agreements with established suppliers for veteran and military healthcare systems. The merger with ReShape Lifesciences consolidates these assets and capabilities, potentially strengthening its competitive position in specialized medical device markets.
• Integration Risk: The merger with ReShape Lifesciences involves combining operations and assets, which may present integration challenges affecting execution and financial performance.
• Regulatory Risk: Medical devices require ongoing regulatory approvals and compliance; changes in regulations or failure to maintain certifications could impact market access.
• Financial Risk: The company reported a net loss and modest revenue, indicating risks related to achieving sustainable profitability and managing cash flow.
• Market Adoption Risk: New medical technologies may face uncertain adoption rates among healthcare providers and patients, impacting revenue growth.
Business trends: The company is consolidating innovative medical device technologies through a merger and securing patents and regulatory certifications to support market access.
Execution milestones: Completion of merger integration, maintaining regulatory compliance, and expanding distribution agreements are key milestones.
Key risks: Integration challenges, regulatory compliance, financial sustainability, and market adoption uncertainties remain significant risks.
High visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Vyome Holdings, Inc is associated with Vyome Therapeutics and involved in a merger with ReShape Lifesciences as of mid-2025.
- ReShape Lifesciences Board unanimously recommended a merger with Vyome Therapeutics and sale of assets to Biorad Medisys in July 2025 [N1].
- ReShape Lifesciences secured multiple patents related to medical devices, including an innovative intragastric device for weight loss solutions [N2], and diabetes neuromodulation technology with key patents in the US and Australia [N4].
- ReShape Lifesciences achieved EU MDR and UKCA certification for its medical devices, enhancing patient safety and market access in Europe [N7].
- ReShape Lifesciences signed exclusive distribution agreements with Recon Supply to distribute devices across VA and DoD systems, targeting veteran and military healthcare solutions [N5][N6].
- ReShape Lifesciences regained Nasdaq compliance with stockholders equity requirements as of June 2025 [N3].
- Financial snapshot as of 2026-09-30 from latest 10-Q filing shows cash and equivalents of $6.96 million, current assets of $7.6 million, current liabilities of $2.07 million, resulting in a current ratio of 3.68 and cash ratio of 3.37, indicating strong liquidity [S2].
- Revenue for the quarter ending 2026-09-30 was $57,998 with a net loss of $885,408 and basic and diluted EPS of -$0.13 per share [S2].
- There have been no material changes to risk factors since the 2025 annual report filed on March 18, 2026 [S2].
Generated 2026-11-15
- S1 | 2026-03-18 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2025-07-21 | www.nasdaq.com | ReShape Lifesciences Board Unanimously Recommends Merger with Vyome Therapeutics and Sale of Assets to Biorad Medisys | https://www.nasdaq.com/articles/reshape-lifesciences-board-unanimously-recommends-merger-vyome-therapeutics-and-sale
- N2 | 2025-07-01 | www.nasdaq.com | ReShape Lifesciences® Secures U.S. Patent for Innovative Intragastric Device Set to Enhance Weight Loss Solutions | https://www.nasdaq.com/articles/reshape-lifesciencesr-secures-us-patent-innovative-intragastric-device-set-enhance-weight
- N3 | 2025-06-27 | www.nasdaq.com | ReShape Lifesciences Inc. Regains Nasdaq Compliance with Stockholders Equity Requirement | https://www.nasdaq.com/articles/reshape-lifesciences-inc-regains-nasdaq-compliance-stockholders-equity-requirement
- N4 | 2025-06-25 | www.nasdaq.com | ReShape Lifesciences® Secures Key Australian Patent for Diabetes Neuromodulation Technology | https://www.nasdaq.com/articles/reshape-lifesciencesr-secures-key-australian-patent-diabetes-neuromodulation-technology
- N5 | 2025-06-12 | www.nasdaq.com | ReShape Signs Exclusive Deal With Recon Supply To Distribute Devices Across VA And DoD Systems | https://www.nasdaq.com/articles/reshape-signs-exclusive-deal-recon-supply-distribute-devices-across-va-and-dod-systems
- N6 | 2025-06-12 | www.nasdaq.com | ReShape Lifesciences Signs Exclusive U.S. Distribution Agreement with Recon Supply for Veteran and Military Healthcare Solutions | https://www.nasdaq.com/articles/reshape-lifesciences-signs-exclusive-us-distribution-agreement-recon-supply-veteran-and
- N7 | 2025-06-03 | www.nasdaq.com | ReShape Lifesciences Achieves EU MDR and UKCA Certification for Medical Devices, Enhancing Patient Safety and Market Access in Europe | https://www.nasdaq.com/articles/reshape-lifesciences-achieves-eu-mdr-and-ukca-certification-medical-devices-enhancing
- N8 | 2025-05-21 | www.nasdaq.com | ReShape Lifesciences Inc. Reports First Quarter 2025 Financial Results and Strategic Updates | https://www.nasdaq.com/articles/reshape-lifesciences-inc-reports-first-quarter-2025-financial-results-and-strategic
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


